12:00 AM
Jan 05, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Advexin regulatory update

EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen withdrew the...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >